|Articles|March 8, 2017
Tufts CSDD Releases Results of New Impact Report
A recently completed study reported that the 505(b)(2) approval pathway for new drug applications in the US has not led to shorter approval times.
Advertisement
A recently completed study conducted by Tufts CSDD reported that the 505(b)(2) approval pathway for new drug applications in the US, aimed at avoiding the duplication of studies performed on a previously approved drugs, has not led to shorter approval times.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Outlines New Superiority Standard for Future CAR-T Approvals
2
Accelerating Clinical Trial Timelines with AI
3
When AI Learns to Speak Every Language: An eCOA Migration Study
4
ACT Brief: AI’s Impact on Trial Timelines, New Strategies in Obesity R&D, and Why Patient Support Needs a Clinical Backbone
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
